A Phase 4 interventional study of Roflumilast Oral Tablet and Azithromycin 250 mg in Chronic Obstructive Pulmonary Disease With Exacerbation, sponsored by Sidra Aziz. Not yet recruiting. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-08-31.
Sponsored by Sidra Aziz · Phase 4, Interventional, and Prevention
"The study is a randomized controlled trial comparing roflumilast and azithromycin as add-on therapies in 70 patients with severe chronic obstructive pulmonary disease (COPD ) and frequent exacerbations. Participants will receive one of the two treatments for six months while continuing standard inhaled therapy. The study aims to determine which drug is more effective in reducing exacerbations and improving clinical outcomes such as forced expiratory volume in one second( FEV1) and modified medical research council ( mMRC)dyspnea scale , hospitalization, adherence, and safety, thereby providing evidence to guide chronic obstructive pulmonary disease management in our local population."
This single-center, randomized controlled trial (RCT) will compare roflumilast and azithromycin as add-on therapies in 70 participants with severe Chronic Obstructive Pulmonary Disease (COPD) and frequent exacerbations. Participants will receive either roflumilast 500 micrograms (µg) orally once daily or azithromycin 250 milligrams (mg) orally once daily for six months, in addition to standard inhaled chronic obstructive pulmonary disease(COPD) therapy. The study will evaluate the comparative effectiveness of these treatments in reducing the frequency and severity of chronic obstructive pulmonary disease (COPD) exacerbations and improving clinical outcomes, including forced expiratory volume in one second (FEV₁), modified Medical Research Council (mMRC) dyspnea score, hospitalization rates, treatment adherence, and safety. The findings are expected to provide local evidence to inform the selection of appropriate add-on therapy for patients with severe chronic obstructive pulmonary disease (COPD) and frequent exacerbations.
Protocol Description Chronic Obstructive Pulmonary Disease (COPD) is a major cause of morbidity and mortality worldwide and is characterized by persistent respiratory symptoms, progressive airflow limitation, and recurrent acute exacerbations. Frequent exacerbations are associated with accelerated decline in lung function, impaired quality of life, increased hospitalization rates, higher healthcare costs, and increased mortality. Despite optimal inhaled therapy, including long-acting bronchodilators with or without inhaled corticosteroids, many patients with severe chronic obstructive pulmonary disease (COPD) continue to experience recurrent exacerbations, underscoring the need for effective add-on therapies.
Roflumilast, an oral selective phosphodiesterase-4 (PDE-4) inhibitor, reduces airway inflammation by increasing intracellular cyclic adenosine monophosphate (cAMP) levels. It has been shown to reduce the frequency of exacerbations, particularly in participants with severe chronic obstructive pulmonary disease (COPD) associated with chronic bronchitis and a history of frequent exacerbations. Azithromycin, a macrolide antibiotic, possesses anti-inflammatory and immunomodulatory properties in addition to its antimicrobial effects and has also demonstrated efficacy in reducing chronic obstructive pulmonary disease (COPD )exacerbations.
However, limited direct comparative evidence exists regarding the relative effectiveness and safety of roflumilast and azithromycin, particularly among patients with severe COPD in the Pakistani population. Accordingly, this study is designed to compare these two therapies as add-on treatments in patients who continue to experience frequent exacerbations despite standard inhaled therapy.
This single-center, randomized controlled trial will enroll 70 eligible patients with severe chronic obstructive pulmonary disease (COPD) and frequent exacerbations using non-probability consecutive sampling. Participants will be randomly assigned in a 1:1 ratio to two treatment groups. One group will receive roflumilast 500 micrograms (µg) orally once daily, while the other will receive azithromycin 250 milligrams (mg) orally once daily. Both treatments will be administered in addition to standard chronic obstructive pulmonary disease (COPD) therapy for six months.
At baseline, participants will undergo a comprehensive clinical assessment, including evaluation of demographic characteristics, smoking history, chronic obstructive pulmonary disease (COPD) history, exacerbation history, co morbidities, medication history, spirometry, and symptom burden using the modified Medical Research Council (mMRC) dyspnea scale. Post-bronchodilator forced expiratory volume in one second (FEV₁) and forced vital capacity (FVC) will be recorded in accordance with standard spirometric procedures.
Participants will be followed at scheduled intervals throughout the six-month treatment period. Follow-up assessments will include the occurrence and severity of COPD exacerbations, hospitalization, changes in post-bronchodilator FEV₁, mMRC dyspnea score, treatment adherence, and adverse drug events. Medication adherence will be assessed using study medication records and participant-reported follow-up information.
The primary outcome will be the reduction in the frequency and severity of chronic obstructive pulmonary disease (COPD) exacerbations during the six-month follow-up period.
Secondary outcomes will include:
The independent-samples t-test will be used to compare normally distributed continuous variables between the two treatment groups. The Mann-Whitney U test will be used for non-normally distributed continuous variables. The chi-square test or Fisher's exact test will be used to compare categorical variables, as appropriate. A p-value of ≤0.05 will be considered statistically significant.
Where appropriate, stratified analyses will be conducted to assess the potential influence of important baseline characteristics and confounding factors, including age, sex, smoking status, baseline forced expiratory volume in one second (FEV₁), baseline forced expiratory volume in one second/forced vital capacity (FEV₁/FVC) ratio, and comorbidities.
The study is expected to provide local evidence regarding the comparative effectiveness, tolerability, and safety of roflumilast and azithromycin as add-on therapies in participants with severe chronic obstructive pulmonary disease (COPD)and frequent exacerbations. The findings may assist clinicians in selecting an appropriate additional pharmacological treatment for participants who continue to experience exacerbations despite standard inhaled therapy.
The Results section will present findings obtained after completion of the six-month follow-up period. Baseline demographic and clinical characteristics will be compared between the roflumilast and azithromycin treatment groups to assess the comparability of the randomized groups.
The primary outcome will be reported as the frequency and severity of Chronic Obstructive Pulmonary Disease (COPD) exacerbations occurring during the six-month follow-up period. The number of exacerbations, the proportion of participants experiencing at least one exacerbation, and exacerbation severity will be compared between the two treatment groups.
Secondary outcomes will include changes in forced expiratory volume in one second (FEV₁), modified Medical Research Council (mMRC) dyspnea score, hospitalization rate, time to first chronic obstructive pulmonary disease (COPD) exacerbation, medication adherence, and adverse drug events.
Spirometric outcomes will be presented using post-bronchodilator forced expiratory volume in one second (FEV₁) and forced vital capacity (FVC). Changes from baseline to the end of the six-month treatment period will be compared between the two treatment groups.
Treatment adherence and adverse drug events will also be reported for both groups. Adverse events will be categorized according to type, frequency, severity, and whether they resulted in treatment discontinuation.
Statistical analysis will be performed using the Statistical Package for the Social Sciences (SPSS), version 27. Continuous variables will be presented as mean ± standard deviation (SD) or median with interquartile range (IQR), according to the distribution of the data. Categorical variables will be presented as frequencies and percentages. Appropriate statistical tests, including the independent-samples t-test, Mann-Whitney U test, chi-square test, and Fisher's exact test, will be applied according to the type and distribution of the data. A p-value of ≤0.05 will be considered statistically significant.
The final results will determine whether roflumilast or azithromycin provides greater benefit in reducing chronic obstructive pulmonary disease (COPD )exacerbations and improving clinical outcomes among patients with severe chronic obstructive pulmonary disease (COPD) and frequent exacerbations receiving standard inhaled therapy.
Exclusion Criteria:
Group A will receive oral roflumilast 500 microgram once daily
Drug: Roflumilast Oral Tablet
Group B will receive oral azithromycin 250 mg once daily
Drug: Azithromycin 250 mg
out of total 70 patients , 35 patients will receive roflumilast 500 microgram once daily
out of 70 patients 35 patients will receive azithromycin 250mg once daily
Number of moderate/severe chronic obstructive pulmonary disease (COPD) exacerbations over 6 months
Reduction in frequency of chronic obstructive pulmonary disease (COPD) exacerbations over 6 months, assessed by the number of moderate/severe exacerbations .
Time frame: 6 months
Proportion of participants requiring hospitalization for COPD exacerbation over 6 months
"Percentage of participants who experience a COPD exacerbation requiring hospital admission during the 6-month treatment period. Hospitalization will be considered COPD-related when the participant is admitted to hospital due to an acute worsening of COPD symptoms requiring inpatient management."
Time frame: 6 months
Changes in Lung Function
Changes in forced expiratory volume in one second to first COPD exacerbation over 6 months
Time frame: 6 months
Hospital admission rate
In this outcome measure frequency of hospital admission will be measured
Time frame: 6 months
Number of participants experiencing treatment-emergent adverse events
The number and proportion of participants experiencing adverse events related to study treatment during the six-month treatment period will be recorded and compared between the roflumilast and azithromycin groups.
Time frame: 6 months
No study locations are listed for this record.
Plan to share: No
This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonary Disease, Chronic Obstructive→